Background. Large-scale, government-based antiretroviral therapy (ART) programs in rural areas of resource-poor countries remain largely unevaluated. Methods. We conducted a retrospective review of all patients receiving ART (n = 399) to assess survival and retention in care and a prospective evaluation of patients on ART for at least 6 months (n = 175). We used 3-day self-report to measure adherence. Results. The probability (95% confidence interval [CI]) of surviving and remaining in care was 0.76 (0.72, 0.81) at 1 year. Men and patients with advanced disease were more likely to die or be lost to follow-up. At baseline, 149 (85%) reported 100% adherence. Nonadherence was associated with lack of suppression of viral replication (odds ratio [OR] = 4.5; 95% CI: 1.8, 11.5). Missing a scheduled clinic visit and lack of disclosure of HIV status were associated with nonadherence. Conclusion. Viral suppression was high, but counseling to include HIV disclosure to family and keeping scheduled clinic appointments may improve long-term adherence and treatment outcomes.
Severe P., Leger P., Charles M., et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti . N Engl J Med. 2005;353:2325-2334.
2.
Spacek LA, Shihab HM, Kamya MR, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis. 2006;42:252-259.
3.
Weidle PJ, Wamai N., Solberg P., et al. Adherence to antiretroviral therapy in a home-based aids care programme in rural Uganda. Lancet. 2006;368:1587-1594.
4.
Nachega JB, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses. 2004;20: 1053-1056.
5.
Byakika-Tusiime J., Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DRAdherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS. 2005;16:38-41.
6.
van Oosterhout JJ, Bodasing N., Kumwenda JJ, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005;10:464-470.
7.
Laniece I., Ciss M., Desclaux A., et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS. 2003;17(suppl 3):S103-S108.
8.
Arnsten JH, Demas PA, Farzadegan H., et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417-1423.
9.
Keiser O., Orrell C., Egger M., et al. Public-health individual approaches to antiretroviral therapy: township South Africa Switzerland compared. PLoS Med.2008;5:e148. doi:10.1371/journal.pmed.0050148.
10.
Laurent C., Kouanfack C., Koulla-Shiro S., et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004 ;364:29-34.
11.
Bourgeois A. , Laurent C., Mougnutou R., et al. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Antivir Ther . 2005;10: 335-341.
12.
Coetzee D., Hildebrand K., Boulle A., et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895.
13.
Laurent C., Diakhate N., Gueye NF, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16: 1363-1370.
14.
Weidle PJ, Malamba S., Mwebaze R., et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360:34-40.
15.
Duong M., Piroth L., Peytavin G., et al. Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response. Clin Infect Dis. 2001;33:386-392.
16.
Fairley CK, Permana A., Read TRLong-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. HIV Med. 2005;6:366-369.
17.
Antinori A., Cozzi-Lepri A., Ammassari A., et al. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther. 2004;9:291-296.
18.
Nieuwkerk PT, Oort FJSelf-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr. 2005;38:445-448.
19.
Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SAPredictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386-395.
20.
Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JEAssociation between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003 ;37:1112-1118.
21.
Melbourne KM , Geletko SM, Brown SL, Willey-Lessne C., Chase S., Fisher A.Medication adherence in patients with HIV infection: a comparison of two measurement methods. AIDS Read . 1999;9:329-338.
22.
Liu H., Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-977.
23.
Paterson DL , Potoski B., Capitano B.Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr. 2002;31(suppl 3):S103-S106.
24.
Calmy A., Ford N., Hirschel B., et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis. 2007;44:128-134.
Bagchi S., Kempf MC, Westfall AO, Maherya A., Willig J., Saag MSCan routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis. 2007;44:135-138.
27.
Rosen S., Fox MP, Gill CJPatient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4:e298. doi:10.371/ journal.pmed.0040298.
28.
Ferradini L. , Jeannin A., Pinoges L., et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006; 367:1335-1342.
29.
Erikstrup C. , Kallestrup P., Zinyama R., et al. Predictors of mortality in a cohort of HIV-1-infected adults in rural Africa. J Acquir Immune Defic Syndr. 2007;44:478-483.
30.
Madec Y., Laureillard D., Pinoges L., et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS . 2007;21:351-359.
31.
Wools-Kaloustian K., Kimaiyo S., Diero L., et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya . AIDS. 2006;20:41-48.
32.
Muyingo SK, Walker AS, Reid A., et al. Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the dart trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr . 2008;48:468-475.
33.
Bisson GP, Rowh A., Weinstein R., Gaolathe T., Frank I., Gross R.Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr. 2008;49: 107-110.
34.
Bisson GP, Gross R., Bellamy S., et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med.2008;5:e109.
35.
San Lio MM, Carbini R., Germano P., et al. Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against aids and malnutrition program in Mozambique. Clin Infect Dis. 2008;46: 1609-1616.
36.
Paterson DL , Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med . 2000;133:21-30.
37.
Singh N., Berman SM, Swindells S., et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29:824-830.
38.
Golin CE, Liu H., Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756-765.
39.
Stirratt MJ , Remien RH, Smith A., Copeland OQ, Dolezal C., Krieger D.The role of HIV serostatus disclosure in antiretroviral medication adherence. AIDS Behav. 2006;10:483-493.
40.
Shah B., Walshe L., Saple DG, et al. Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India . Clin Infect Dis. 2007;44:1235-1244.
41.
Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255-266.
42.
Walsh JC, Horne R., Dalton M., Burgess AP, Gazzard BGReasons for non-adherence to antiretroviral therapy: patients' perspectives provide evidence of multiple causes. AIDS Care. 2001;13:709-720.
